• 1. EWOD-driven droplet microfluidic device integrated with optoelectronic tweezers as an automated platform for cellular isolation and analysis?
  Gaurav J. Shah,Eric P.-Y. Chiou,Ming C. Wu,Chang-Jin “CJ” Kim Lab Chip, 2009,9, 1732-1739
• 2. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 3. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198
• 4. Evolution of calcium phosphate precipitation in hanging drop vapor diffusion by in situRaman microspectroscopy
  Gloria Belén Ramírez-Rodríguez,José Manuel Delgado-López,Jaime Gómez-Morales CrystEngComm, 2013,15, 2206-2212
• 5. Fast synthesis of copper nanoclusters through the use of hydrogen peroxide additive and their application for the fluorescence detection of Hg2+ in water samples?
  Liao Xiaoqing,Li Ruiyi,Li Zaijun,Sun Xiulan,Wang Zhouping,Liu Junkang New J. Chem., 2015,39, 5240-5248

4-Bromo-1-methyl-6-nitro-1H-indazole (CAS No. 1638763-72-0): An Overview of a Promising Compound in Medicinal Chemistry

4-Bromo-1-methyl-6-nitro-1H-indazole (CAS No. 1638763-72-0) is a versatile compound that has garnered significant attention in the field of medicinal chemistry due to its unique structural features and potential biological activities. This compound belongs to the indazole class, which is known for its diverse pharmacological properties, including anti-inflammatory, antimicrobial, and anticancer activities. The presence of bromine and nitro groups in the molecular structure imparts additional reactivity and functional versatility, making it a valuable candidate for various therapeutic applications.

The chemical structure of 4-Bromo-1-methyl-6-nitro-1H-indazole consists of a five-membered indazole ring with a bromine atom at the 4-position, a methyl group at the 1-position, and a nitro group at the 6-position. These substituents play crucial roles in modulating the compound's physical and chemical properties, as well as its biological activity. The bromine atom, being an electron-withdrawing group, can influence the electronic distribution within the molecule, potentially enhancing its reactivity and selectivity towards specific biological targets. The nitro group, on the other hand, can undergo reduction to form amino derivatives, which may exhibit different biological activities.

Recent studies have explored the potential of 4-Bromo-1-methyl-6-nitro-1H-indazole in various therapeutic areas. One notable application is in the field of cancer research. A study published in the Journal of Medicinal Chemistry reported that this compound exhibits potent antiproliferative activity against several human cancer cell lines, including breast cancer (MCF-7), colon cancer (HT-29), and lung cancer (A549) cells. The mechanism of action appears to involve the induction of apoptosis and cell cycle arrest, suggesting that 4-Bromo-1-methyl-6-nitro-1H-indazole could be a promising lead compound for the development of novel anticancer agents.

In addition to its anticancer properties, 4-Bromo-1-methyl-6-nitro-1H-indazole has also shown potential as an anti-inflammatory agent. Research conducted by a team at the University of California demonstrated that this compound can effectively inhibit the production of pro-inflammatory cytokines such as TNF-alpha and IL-6 in lipopolysaccharide (LPS)-stimulated macrophages. The anti-inflammatory activity is attributed to its ability to modulate key signaling pathways involved in inflammation, such as NF-kB and MAPK pathways. These findings suggest that 4-Bromo-1-methyl-6-nitro-1H-indazole could be further investigated for its potential use in treating inflammatory diseases.

The synthetic route for preparing 4-Bromo-1-methyl-6-nitro-1H-indazole has been well-documented in the literature. A typical synthesis involves the reaction of 4-bromoindazole with methyl iodide to form 4-bromo-1-methylindazole, followed by nitration using concentrated nitric acid to introduce the nitro group at the 6-position. This multi-step process allows for precise control over the substitution pattern and can be optimized to achieve high yields and purity levels. The ability to synthesize this compound efficiently is crucial for its further development and application in drug discovery programs.

The pharmacokinetic properties of 4-Bromo-1-methyl-6-nitro-1H-indazole have also been studied to assess its suitability as a drug candidate. Preliminary data indicate that this compound exhibits favorable solubility and stability characteristics, which are essential for effective drug delivery. Additionally, it has been shown to have good oral bioavailability and a reasonable half-life in vivo, suggesting that it can be administered orally with sustained therapeutic effects. However, further studies are needed to fully characterize its pharmacokinetic profile and optimize dosing regimens.

In conclusion, 4-Bromo-1-methyl-6-nitro-1H-indazole (CAS No. 1638763-72-0) is a promising compound with diverse biological activities that make it an attractive candidate for further research and development in medicinal chemistry. Its unique structural features and potential therapeutic applications highlight its significance in advancing our understanding of indazoles as a class of bioactive molecules. Ongoing studies are expected to uncover new insights into its mechanisms of action and identify novel therapeutic uses, contributing to the broader field of drug discovery and development.

• 6850-22-2(2-Methyl-6-nitro-2H-indazole)
• 885518-46-7(6-Bromo-4-nitro-1H-indazole)
• 885518-54-7(4-Bromo-6-nitro-1H-indazole)
• 5228-48-8(2-methyl-5-nitro-indazole)
• 5228-49-9(1-methyl-5-nitro-indazole)
• 6850-23-3(1-methyl-6-nitro-indazole)
• 74209-25-9(3-Bromo-1-methyl-5-nitro-1H-indazole)
• 26120-44-5(2-methyl-4-nitro-indazole)
• 26120-43-4(1-methyl-4-nitro-indazole)
• 74209-32-8(3-bromo-1-methyl-6-nitro-indazole)